WebTriple therapy, a combination of oral anticoagulant (OAC) plus dual antiplatelet therapy with aspirin and P2Y12inhibitor, has been used for patients with AF undergoing PCI in recent decades to reduce ischemic events under guideline recommendations. However, triple therapy is well-known to induce severe bleeding events. WebMay 20, 2024 · The optimal antithrombotic treatment in patients receiving oral anticoagulation undergoing percutaneous coronary intervention (PCI) has been a field of intensive research. Although triple antithrombotic therapy had been, until lately, the strategy of choice, recent evidence points to the superiority of dual antithrombotic …
Duration of Triple Therapy in Patients Requiring Oral Anticoagulati…
WebJan 1, 2024 · The duration of triple therapy is recommended to be as short as possible. The ISAR-TRIPLE trial, in which 614 patients were randomized to 6-week versus 6 … WebDec 9, 2024 · Synopsis. After PCI, the use of DAPT prevents stent thrombosis and reduces ischemic events at the cost of increased bleeding. 5 Pooled data have demonstrated less bleeding with shorter-term DAPT … ear is leaking fluid
UpToDate
WebMost studies show a decreased stroke and myocardial infarction risk, but an increased risk of bleeding events in case of triple therapy. There is general agreement that, when possible, the duration of triple therapy should be shortened followed by clopidogrel and an oral anticoagulant to minimize bleeding risk without increasing other adverse ... WebOct 1, 2015 · In registries of patients who received triple therapy after PCI, the rate of major bleeding or need for blood transfusion ranged from approximately 5 % early after PCI to more than 10 % at 12 months. [ 1–4] In a nationwide Danish registry of 11,480 patients with AF who were admitted for MI or PCI between 2001 and 2009, bleeding requiring … WebNov 1, 2024 · After percutaneous intervention (PCI), dual antiplatelet therapy (DAPT) with aspirin and a P2Y12inhibitor is recommended to prevent stent thrombosis.1,2Many of these patients have coexisting atrial fibrillation (AF), mechanical heart valve in place or have venous thromboembolism that warrants concomitant use of uninterrupted oral … cssf 22/808